Division of Vascular Surgery, Department of Surgery, NYU Langone Health, New York, NY; Division of Vascular & Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA.
Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY.
Ann Vasc Surg. 2021 Oct;76:10-19. doi: 10.1016/j.avsg.2021.03.001. Epub 2021 Apr 7.
Adjunctive false lumen embolization (FLE) with thoracic endovascular aortic repair (TEVAR) in patients with chronic aortic dissection is thought to induce FL thrombosis and favorable aortic remodeling. However, these data are derived from small single-institution experiences and the potential benefit of FLE remains unproven. In this study, we examined perioperative and midterm outcomes of patients with aortic dissection undergoing concomitant TEVAR and FLE.* METHODS: : Patients 18 or older who underwent TEVAR for chronic aortic dissection with known FLE status in the Society for Vascular Surgery Vascular Quality Initiative database between January 2010 and February 2020 were included. Ruptured patients and emergent procedures were excluded. Patient characteristics, operative details and outcomes were analyzed by group: TEVAR with or without FLE. Primary outcomes were in-hospital post-operative complications and all-cause mortality. Secondary outcomes included follow-up mean maximum aortic diameter change, rates of false lumen thrombosis, re-intervention rates, and mortality.
884 patients were included: 46 had TEVAR/FLE and 838 had TEVAR alone. There was no significant difference between groups in terms of age, gender, comorbidities, prior aortic interventions, mean maximum pre-operative aortic diameter (5.1cm vs. 5.0cm, P=0.43), presentation symptomatology, or intervention indication. FLE was associated with significantly longer procedural times (178min vs. 146min, P=0.0002), increased contrast use (134mL vs. 113mL, P=0.02), and prolonged fluoroscopy time (34min vs. 21min, P<0.0001). However, FLE was not associated with a significant difference in post-operative complications (17.4% vs. 13.8%, P=0.51), length of stay (6.5 vs. 5.7 days, P=0.18), or in-hospital all-cause mortality (0% vs. 1.3%, P=1). In mid-term follow-up (median 15.5months, IQR 2.2-36.2 months), all-cause mortality trended lower, but was not significant (2.2% vs. 7.8%); and Kaplan-Meier analysis demonstrated no difference in overall survival between groups (P=0.23). By Cox regression analysis, post-operative complications had the strongest independent association with all-cause mortality (HR 2.65, 95% CI 1.56-4.5, P<0.001). In patients with available follow-up imaging and re-intervention status, mean aortic diameter change (n=337, -0.71cm vs. -0.69cm, P=0.64) and re-intervention rates (n=487, 10% vs. 11.4%, P=1) were similar.
Adjunctive FLE, despite increased procedural times, can be performed safely for patients with chronic dissection without significantly higher overall perioperative morbidity or mortality. TEVAR/FLE demonstrates trends for improved survival and increased rates of FL thrombosis in the treated thoracic segment; however, given the lack of evidence to suggest a significant reduction in re-intervention rates or induction of more favorable aortic remodeling compared to TEVAR alone, the overall utility of this technique in practice remains unclear. Further investigation is needed to determine the most appropriate role for FLE in managing chronic aortic dissections.
在慢性主动脉夹层患者中,胸主动脉腔内修复术(TEVAR)辅助假腔栓塞(FLE)被认为可诱导 FL 血栓形成和有利的主动脉重塑。然而,这些数据来自于小的单中心经验,FLE 的潜在益处仍未得到证实。在这项研究中,我们研究了在血管外科学会血管质量倡议数据库中接受 TEVAR 治疗的慢性主动脉夹层患者的围手术期和中期结果,这些患者已知 FLE 状态。排除破裂患者和紧急手术。通过组分析患者特征、手术细节和结果:TEVAR 伴或不伴 FLE。主要结果是住院术后并发症和全因死亡率。次要结果包括随访平均最大主动脉直径变化、假腔血栓形成率、再干预率和死亡率。
共纳入 884 例患者:46 例行 TEVAR/FLE,838 例行 TEVAR 单独治疗。两组在年龄、性别、合并症、既往主动脉干预、术前平均最大主动脉直径(5.1cm 对 5.0cm,P=0.43)、表现症状或干预指征方面无显著差异。FLE 与明显较长的手术时间(178 分钟对 146 分钟,P=0.0002)、增加的对比剂使用(134 毫升对 113 毫升,P=0.02)和延长的透视时间(34 分钟对 21 分钟,P<0.0001)相关。然而,FLE 与术后并发症(17.4%对 13.8%,P=0.51)、住院时间(6.5 天对 5.7 天,P=0.18)或院内全因死亡率(0%对 1.3%,P=1)无显著差异。在中期随访(中位数 15.5 个月,IQR 2.2-36.2 个月)中,全因死亡率虽有下降趋势,但无统计学意义(2.2%对 7.8%);Kaplan-Meier 分析显示两组之间的总体生存率无差异(P=0.23)。通过 Cox 回归分析,术后并发症与全因死亡率有最强的独立相关性(HR 2.65,95%CI 1.56-4.5,P<0.001)。在有随访影像学和再干预状态的患者中,平均主动脉直径变化(n=337,-0.71cm 对-0.69cm,P=0.64)和再干预率(n=487,10%对 11.4%,P=1)相似。
尽管辅助 FLE 增加了手术时间,但在慢性夹层患者中安全实施,不会显著增加围手术期整体发病率或死亡率。TEVAR/FLE 显示出在治疗的胸段中改善生存和增加假腔血栓形成的趋势;然而,由于没有证据表明与 TEVAR 单独治疗相比,这种技术能显著降低再干预率或诱导更有利的主动脉重塑,因此该技术在实践中的总体效用尚不清楚。需要进一步研究以确定 FLE 在治疗慢性主动脉夹层中的最佳作用。